Heated intraperitoneal mitomycin C infusion treatment for patients with gastric cancer and peritoneal metastasis

  • Shigeru Fujimoto
  • Makoto Takahashi
  • Kokuriki Kobayashi
  • Junji Kasanuki
  • Haruo Ohkubo
Part of the Cancer Treatment and Research book series (CTAR, volume 81)

Abstract

The vast majority of peritoneal carcinomatosis occurs in the form of a secondary metastatic lesion. In Japan, the stomach is the most frequent origin of metastatic cancer in the abdominal cavity, while in Western countries the ovary is usually affected. The bile duct, large intestine, and breast are other primary sites. With cancerous invasion of the peritoneoserosal membrane, ascitic fluid frequently accumulates in the abdominal cavity and a terminal state can be thus identified.

Keywords

Catheter Lactate Heparin MgCl Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1–11.PubMedGoogle Scholar
  2. 2.
    Dedrick RL, Flessner MF, Collins JM, Schultz JS. Is the peritoneum a membrane? ASAIO J 1982;5:1–8.Google Scholar
  3. 3.
    Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12:1–6.PubMedGoogle Scholar
  4. 4.
    Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Fujimoto S, Shretha MD, Kobayashi K, Koike S, Kokubun M, Kiuchi S, Takahashi M, Konno C, Okui K. Combined treatment with surgery and intraperitoneal hyperthermic perfusion (IPHP) for far-advanced gastrointestinal cancer with peritoneal seeding. Acta Med Austriaca 1989;16:76–80.PubMedGoogle Scholar
  6. 6.
    Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Takahashi M, Okui K. Pharmacokinetic analysis of mitomycin C for intraperitoneal hyperthermic perfusion in patients with far-advanced or recurrent gastric cancer. Reg Cancer Treat 1989;2:198–202.Google Scholar
  7. 7.
    Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Takahashi M, Konno C, Ohta M, Kitsukawa Y, Mizutani M, Okui K. Clinical trials with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989;64:154–160.PubMedCrossRefGoogle Scholar
  8. 8.
    Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Ohta M, Takahashi M, Kitsukawa Y, Mizutani M, Chikenji T, Okui K. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592–596.PubMedCrossRefGoogle Scholar
  9. 9.
    Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Takahashi M, Okui K. Clinical outcome of combined therapy of intraoperative hyperthermochemotherapy and surgery for patients with peritoneal recurrence from gastric cancer. Reg Cancer Treat 1990;3:181–184.Google Scholar
  10. 10.
    Fujimoto S, Takahashi M, Kobayashi K, Nagano K, Kure M, Mutou T, Ohkubo H. Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients with gastric cancer with peritoneal metastasis. Cancer 1992;70:2754–2760.PubMedCrossRefGoogle Scholar
  11. 11.
    Fujimoto S, Takahashi M, Kabayashi K, Kure M, Mutou T, Masaoka H, Ohkubo H. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology 1993;50:338–343.PubMedCrossRefGoogle Scholar
  12. 12.
    Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasagawa H, Katayama K, Miwa K, Miyazaki I. Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 1990;65:65–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Iitsuka Y, Kaneshima S, Tanida O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 1979;44:1476–1480.PubMedCrossRefGoogle Scholar
  14. 14.
    Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–237.PubMedCrossRefGoogle Scholar
  15. 15.
    Sugarbaker PH, Landy D, Jaffe G, Pascal R. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon and appendix. Cancer 1990;65:1495–1501.PubMedCrossRefGoogle Scholar
  16. 16.
    Wangensteen OH, Lewis FJ, Tongen LA. The second-look in cancer surgery. Lancet 1951;71:303–307.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Shigeru Fujimoto
  • Makoto Takahashi
  • Kokuriki Kobayashi
  • Junji Kasanuki
  • Haruo Ohkubo

There are no affiliations available

Personalised recommendations